Biotechnology

Faron Pharmaceuticals Presents Phase II Data from BEXMAB Study at ASCO 2025

June 2, 2025 2:30 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Favorable response rates and survival data in high/very high-risk frontline and r/r MDS support advancement to Phase III trial in frontline MDS, per previous FDA guidance Median overall survival of 13.4 months in 32 r/r MDS patients treated with bexmarilimab + azacitidine ORR of 63% and 72% observed in patients with r/r MDS (n=32) and frontline MDS patients (n=18), respectively 56% composite CR (cCR)...

Read more

Riboscience Announces Successful Completion of Phase 1a Dose Escalation for RBS2418, a New Anti-Cancer Immunotherapy

May 30, 2025 9:00 AM

Riboscience, LLC, today announced the presentation of data from the completed dose escalation Phase 1a of the Phase 1a/b clinical trial of the ENPP1 inhibitor RBS2418 that will be delivered by Dr. Thomas U. Marron, MD, PhD, from Mount Sinai, New York at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. RBS2418 is the first ENPP1 inhibitor in clinical development. Clinical study RBS2418-1001 (NCT05270213)...

Read more

Faron Announces Publication of Full Phase I BEXMAB Study Data in Lancet Haematology

May 30, 2025 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in high-risk and HMA-refractory MDS patients Key findings: Bexmarilimab in combination with azacitidine showed ORR of 100% and 89% in treatment-naïve and HMA-failed HR-MDS patients, respectively Majority of treatment-emergent adverse events (TEAE) were mild to moderate, and only 6% were related to...

Read more

NAYA Therapeutics Enters into Definitive Agreements to Regain Full Rights to Next-Generation Cancer Immunotherapies As It Advances Towards Clinical Milestones

May 29, 2025 9:00 AM

NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer immunotherapies, has regained its status as a privately-held company, separating from its recent merger with INVO Bioscience. This strategic decision enables NAYA Therapeutics to optimize its portfolio development strategy for value maximization and market attractiveness as it advances towards clinical development milestones for...

Read more

Bionoid Pharma, Inc. Confirms Name Change to AI Maverick Intel, Inc. Following Delaware Approval

May 29, 2025 7:30 AM

Bionoid Pharma, Inc. (OTC PINK:BINP) ("Bionoid" or the "Company") is pleased to confirm that, following the previously announced rebranding initiative, the State of Delaware has approved the Company's formal name change to AI Maverick Intel, Inc., effective April 30, 2025. The Company has submitted the necessary filings with FINRA to update its name and trading symbol on the OTC Markets. Subject to FINRA's approval, the name and symbol change...

Read more

Vicore to Present at the Jefferies Global Healthcare Conference

May 28, 2025 2:20 AM

Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the Jefferies Global Healthcare Conference: Location: New York, USA Format: Presentation and 1x1 meetings Presentation Date and Time: Thursday, June 5 at 4:20 PM ET Webcast: https://wsw.com/webcast/jeff319/vico/1857304 Participants: Ahmed Mousa, CEO, and Megan Richards, VP of...

Read more

Redefining the Healthcare Frontier: How Lee Tafoya is Engineering the Future of Patient-Centered Innovation

May 27, 2025 11:55 PM

In an era where healthcare systems grapple with complexity, inefficiency, and increasing demands for accessibility, few individuals rise to the challenge with the clarity and conviction of Lee A. Tafoya. A former nurse and now a dynamic business strategist, Lee is not just improving healthcare, he is helping redefine its foundations. With a powerful blend of clinical insight, business acumen, and ethical clarity, he is building a future in which...

Read more

Bora Biologics Expands San Diego Facility for 2000L+ Scale Biologics Manufacturing, Boosts CDMO Capacity

May 27, 2025 3:45 PM

Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego. This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics' position as a...

Read more

Archetype Therapeutics Announces Scientific Advisory Board

May 27, 2025 10:00 AM

Archetype Therapeutics, a drug discovery company that uses generative AI to rapidly screen billions of potential drugs virtually for their clinical impact in genomically-defined patient cohorts, today announced the formation of its Scientific Advisory Board (SAB) to help advance its preclinical programs and Archetype™ discovery platform. William K. Oh, MD, a distinguished medical oncologist and early advisor to Archetype, serves as the Founding...

Read more

Bora Biologics Expands San Diego Facility for 2000L+ Scale Biologics Manufacturing, Boosts CDMO Capacity

May 27, 2025 7:00 AM

Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics manufacturing, announced a major expansion of its U.S. FDA-registered commercial manufacturing facility in San Diego. This expansion will add state-of-the-art upstream and downstream GMP processing capabilities to meet the increasing demand for 2000L scale single-use biologics manufacturing, solidifying Bora Biologics' position as a...

Read more

Faron’s Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid Malignancies

May 27, 2025 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases antigen presentation and overcoming resistance to standard-of-care drugs Study highlights: Ex vivo treatment of AML and MDS bone marrow samples with bexmarilimab led to increased antigen-presenting human leukocyte antigen DR isotype (HLA-DR) expression, indicating improved antigen presentation...

Read more

Alligator Bioscience AB Carries Out Directed Issues to Guarantors in Connection with Exercise of Warrants Series TO 12

May 26, 2025 12:15 PM

Alligator Bioscience (STO:ATORX) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The Board of Directors of Alligator...

Read more

Alligator Bioscience Announces European Orphan Drug Designation for HLX22 in Gastric Cancer

May 26, 2025 9:15 AM

Alligator Bioscience (STO:ATORX) - Lund, Sweden - 26 May 2025 - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the European Commission has granted orphan drug designation (ODD) to HLX22, an anti-HER2 monoclonal antibody, for the treatment of gastric cancer. HLX22 is being developed by Shanghai Henlius Biotech, Inc. under a sublicense from AbClon, Inc., which had previously licensed the antibody from Alligator. This...

Read more

Alligator Bioscience Presents OPTIMIZE-1 Biomarker Data at ASCO 2025 Annual Meeting

May 23, 2025 3:05 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced the presentation of biomarker data from its OPTIMIZE-1 clinical trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. OPTIMIZE-1 is an ongoing Phase 1b/2 trial of mitazalimab in combination with mFOLFIRINOX in first-line metastatic pancreatic cancer (mPDAC). The trial has demonstrated strong clinical outcomes to date, including a ~30% survival rate at...

Read more

New DiviTum(R) TKa Data to be Presented at ASCO in Three Cancer Types

May 23, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest cancer meeting, the American Society of Clinical Oncology (ASCO), May 30 - June 3, 2025. ASCO is the world's largest and most influential oncology conference, bringing together approximately 31,000 oncology professionals....

Read more

Faron Announces New Data that Highlight Patient Populations with Cancer that are Most Likely to Benefit from First-in-class Immunotherapy Bexmarilimab

May 23, 2025 2:20 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New data published in the Journal for ImmunoTherapy of Cancerreveals how tumor microenvironment shapes response to bexmarilimab along with a gene signature that can predict sensitivity to treatment Study highlights: Tissuemicroenvironments showed three distinct response patterns to bexmarilimab , driven by the level of inflammation, macrophage type, and their location within the tissue. Bexmarilimab...

Read more

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 22, 2025 9:30 AM

IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region. Approximately 12.5% of Puerto Ricans over the age of 65 have Alzheimer's, a figure notably higher than the roughly 10%...

Read more

Vicore Presents New Data at the 2025 American Thoracic Society International Conference

May 22, 2025 3:25 AM

Vicore Pharma Holding (STO:VICO) - Stockholm, May 22, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company delivered multiple oral presentations and posters this week at the 2025 American Thoracic Society (ATS) International Conference, held May 16-21, 2025. "The presentations at this year's ATS conference underscore the...

Read more

Alligator Bioscience AB Announces Final Outcome of Exercise of Warrants Series TO 12

May 21, 2025 9:00 AM

Alligator Bioscience (STO:ATORX) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The exercise period for warrants...

Read more

Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets

May 21, 2025 9:00 AM

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces that it has received a staff determination letter from the Nasdaq Stock Market, LLC ("Nasdaq"), informing the Company that Nasdaq determined to suspend trading and delist the Company's common stock from Nasdaq. At the open of trading on...

Read more